
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1103 | 1092 | 1129 | 1121 | 1450 | 2123 |
Fund Return | 10.28% | 9.19% | 12.92% | 3.87% | 7.71% | 7.82% |
Place in category | 312 | 228 | 434 | 292 | 134 | 22 |
% in Category | 45 | 33 | 66 | 51 | 31 | 7 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet CH Institutional Swiss EquiI | 2.29B | 10.19 | 3.38 | 7.31 | ||
Pictet CH Institutional Swiss EquiP | 2.29B | 10.16 | 3.18 | 7.09 | ||
Pictet CH Institutional Swiss EquiZ | 2.29B | 8.90 | 2.54 | 8.57 | ||
Pictet CH Institutional Swiss EquID | 2.29B | 4.62 | -3.37 | 6.34 | ||
Pictet CH Institutional Swiss EquPD | 2.29B | 4.41 | -3.57 | 6.13 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.72B | 12.09 | 5.90 | 7.10 | ||
Pictet CH Institutional Swiss EquiI | 2.29B | 10.19 | 3.38 | 7.31 | ||
Pictet CH Institutional Swiss EquiP | 2.29B | 10.16 | 3.18 | 7.09 | ||
Pictet CH Institutional Swiss EquiZ | 2.29B | 8.90 | 2.54 | 8.57 | ||
UBS CH Equity Fund Swiss Income CHF | 2.63B | 8.29 | 0.69 | 5.71 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Roche Holding Participation | CH0012032048 | 13.13 | 306.40 | -0.91% | |
Nestle | CH0038863350 | 10.92 | 90.44 | -1.35% | |
Novartis | CH0012005267 | 9.90 | 98.61 | -0.62% | |
ABB | CH0012221716 | 6.61 | 50.08 | +0.18% | |
Zurich Insurance Group | CH0011075394 | 6.20 | 610.00 | -0.16% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review